Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.50 Consensus Target Price from Analysts

Acelyrin, Inc. (NASDAQ:SLRN) has received a consensus recommendation of “Hold” from the five research firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $11.40.

Several research firms recently commented on SLRN. Piper Sandler reduced their target price on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. HC Wainwright lifted their price objective on Acelyrin from $6.00 to $8.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Morgan Stanley dropped their target price on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating for the company in a report on Monday, August 19th. Finally, Wells Fargo & Company lifted their price target on Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 16th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SLRN. Ameritas Investment Partners Inc. grew its position in shares of Acelyrin by 118.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company’s stock worth $49,000 after buying an additional 3,921 shares during the last quarter. Principal Financial Group Inc. purchased a new position in Acelyrin during the 2nd quarter valued at $49,000. Virtu Financial LLC bought a new position in Acelyrin in the 3rd quarter worth $50,000. HighTower Advisors LLC purchased a new stake in shares of Acelyrin in the 3rd quarter worth about $50,000. Finally, SG Americas Securities LLC bought a new stake in shares of Acelyrin during the 2nd quarter valued at about $51,000. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Acelyrin Stock Performance

SLRN stock opened at $4.57 on Friday. The company has a market capitalization of $458.51 million, a PE ratio of -1.86 and a beta of 1.98. Acelyrin has a one year low of $3.36 and a one year high of $8.89. The company’s 50 day moving average price is $5.38 and its two-hundred day moving average price is $5.02.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.